Skip to content

Novartis Pushes Forward With Covid Drug After Positive Trial

  • Therapy is found to reduce amount of virus within eight days
  • Drugmaker to license medicine from Molecular Partners
Updated on

Novartis AG will push forward with a potential medicine for Covid-19 after promising results showing a lower risk of bad outcomes for patients who took the antiviral in a mid-sized study. 

Covid patients who took the therapy, ensovibep, had a 78% lower risk of needing an emergency health-care visit, being hospitalized or dying in the 407-person test, the companies said Monday. The compound also cleared the main hurdle of the study, which was to reduce the amount of virus in the body over eight days.